Human intestinal P-glycoprotein activity estimated by the model substrate digoxin.
about
Pharmacogenetics in chronic heart failure: new developments and current challengesDiscovery of the inhibitory effect of a phosphatidylinositol derivative on P-glycoprotein by virtual screening followed by in vitro cellular studiesClinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort studyLow ABCB1 gene expression is an early event in colorectal carcinogenesis.High ABCC2 and low ABCG2 gene expression are early events in the colorectal adenoma-carcinoma sequence.The multidrug resistance 1 (MDR1) gene polymorphism G-rs3789243-A is not associated with disease susceptibility in Norwegian patients with colorectal adenoma and colorectal cancer; a case control studyEnhanced activity of doxorubicin in drug resistant A549 tumor cells by encapsulation of P-glycoprotein inhibitor in PLGA-based nanovectors.Multidrug resistance in the chronic lymphoproliferative disorders.Transporter-mediated drug-drug interactions.Verapamil and rifampin effect on p-glycoprotein expression in hepatocellular carcinoma.Post-mortem ABCB1 genotyping reveals an elevated toxicity for female digoxin users.Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population.PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin
P2860
Q26852239-73E1363E-412C-41E2-A73D-418CB4BC51CEQ28486121-D5E5DAB4-2A66-4825-B2AF-4D8EAD866573Q30234940-A01EE35E-3FF8-47F0-BFC3-CE63D97D5917Q30907350-75DA92F4-1EC5-4ACB-9E16-644525A7FF17Q34973313-F19F807F-9C82-4628-ACBD-C1CCA4CAC58BQ35202603-65796802-4674-4E5E-8876-1F347DF0FF67Q37144058-91D6D09B-2E16-468B-ABC0-BCDAEAFD5A45Q37438008-E3022D7D-F92C-4A1A-A99C-7955BCB2DD87Q37771031-75FC3C95-8EB9-4146-883E-8F6AFA59D5C8Q37905033-BF0F536D-2826-4979-8E53-D351F27579CCQ42173807-CFC169CD-5B7A-4F81-BF75-8F93B64EBF55Q42751321-87D00C9A-DAA2-4BAD-B68A-44E2FF9FCC08Q48301397-3849B16A-D11C-4E7D-AC5A-2765C310CEE4Q50548303-87471740-2276-49F3-836B-FB009384E28CQ58758044-D085300C-2BC2-49B3-9E46-54EB8EF1C438
P2860
Human intestinal P-glycoprotein activity estimated by the model substrate digoxin.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Human intestinal P-glycoprotein activity estimated by the model substrate digoxin.
@en
Human intestinal P-glycoprotein activity estimated by the model substrate digoxin.
@nl
type
label
Human intestinal P-glycoprotein activity estimated by the model substrate digoxin.
@en
Human intestinal P-glycoprotein activity estimated by the model substrate digoxin.
@nl
prefLabel
Human intestinal P-glycoprotein activity estimated by the model substrate digoxin.
@en
Human intestinal P-glycoprotein activity estimated by the model substrate digoxin.
@nl
P2093
P2860
P1476
Human intestinal P-glycoprotein activity estimated by the model substrate digoxin.
@en
P2093
Andersen V
Guldborg Nyvold C
Hyldahl Olesen L
Jakobsen P
Østergaard M
P2860
P304
P356
10.1080/00365510600986084
P577
2007-01-01T00:00:00Z